The rRNA synthesis inhibitor CX-5461 may induce autophagy that inhibits anticancer drug-induced cell damage to leukemia cells

References

• Muzushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147:728–741.
   PubMed Web of Science ®Google Scholar
• Kondo Y, Kondo S. Autophagy and cancer therapy. Autophagy. 2006;2:85–90.
   PubMed Web of Science ®Google Scholar
• Chittaranjan S, Bortnik S, Dragowska WH, et al. Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer. Clin Cancer Res. 2014;20:3159–3173.
   PubMed Web of Science ®Google Scholar
• Aveic S, Pantile M, Polo P, et al. Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors. Cancer Cell Int. 2018;18:63.
   PubMed Web of Science ®Google Scholar
• Sui X, Chen R, Wang Z, et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis. 2013;4:e838.
   PubMed Web of Science ®Google Scholar
• Schweichel JU, Merker HJ. The morphology of various types of cell death in prenatal tissues. Teratology. 1973;7:253–266.
   PubMedGoogle Scholar
• Shen HM, Codogno P. Autophagic cell death: Loch Ness monster or endangered species? Autophagy. 2011;7:457–465.
   PubMed Web of Science ®Google Scholar
• Klionsky DJ, Abdelmohsen K, Abe A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12:1–222.
   PubMed Web of Science ®Google Scholar
• Okamoto S, Tsujioka T, Suemori S, et al. Withaferin A suppresses the growth of myelodysplasia and leukemia cell lines by inhibiting cell cycle progression. Cancer Sci. 2016;107:1302–1314.
   PubMed Web of Science ®Google Scholar
• Samaras P, Tusup M, Nguyen-Kim TDL, et al. Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer. Cancer Chemother Pharmacol. 2017;80:1005–1012.
   PubMed Web of Science ®Google Scholar
• Manic G, Obrist F, Kroemer G, et al. Chloroquine and hydroxychloroquine for cancer therapy. Mol Cell Oncol. 2014;1:e29911.
   PubMedGoogle Scholar
• Shi TT, Yu XX, Yan LJ, et al. Research progress of hydroxychloroquine and autophagy inhibitors on cancer. Cancer Chemother Pharmacol. 2017;79:287–294.
   PubMed Web of Science ®Google Scholar
• Derenzini M, Trerè D, Pession A, et al. Nucleolar function and size in cancer cells. Am J Pathol. 1998;152:1291–1297.
   PubMed Web of Science ®Google Scholar
• Ruggero D, Pandolfi PP. Does the ribosome translate cancer? Nat Rev Cancer. 2003;3:179–192.
   PubMed Web of Science ®Google Scholar
• Rossetti S, Wierzbicki AJ, Sacchi N. Mammary epithelial morphogenesis and early breast cancer. Evidence of involvement of basal components of the RNA Polymerase I transcription machinery. Cell Cycle. 2016;15:2515–2526.
   PubMed Web of Science ®Google Scholar
• White RJ. RNA polymerases I and III, growth control and cancer. Nat Rev Mol Cell Biol. 2005;6:69–78.
   PubMed Web of Science ®Google Scholar
• Drygin D, Lin A, Bliesath J, et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res. 2011;71:1418–1430.
   PubMed Web of Science ®Google Scholar
• Li L, Li Y, Zhao J, et al. CX-5461 induces autophagy and inhibits tumor growth via mammalian target of rapamycin-related signaling pathways in osteosarcoma. Oncol Targets Ther. 2016;9:5985–5997.
   PubMed Web of Science ®Google Scholar
• Chen H, Duo Y, Hu B, et al. PICT-1 triggers a pro-death autophagy through inhibiting rRNA transcription and AKT/mTOR/p70S6K signaling pathway. Oncotarget. 2016;7:78747–78763.
   PubMedGoogle Scholar
• Hein N, Cameron DP, Hannan KM, et al. Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. Blood. 2017;129:2882–2895.
   PubMed Web of Science ®Google Scholar
• Lee HC, Wang H, Baladandayuthapani V, et al. RNA polymerase I inhibition with CX-5461 as a novel therapeutic strategy to target MYC in multiple myeloma. Br J Haematol. 2017;177:80–94.
   PubMed Web of Science ®Google Scholar
• Bywater MJ, Poortinga G, Sanij E, et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell. 2012;22:51–65.
   PubMed Web of Science ®Google Scholar
• Devlin JR, Hannan KM, Hein N, et al. Combination therapy targeting ribosome biogenesis and mRNA translation synergistically extends survival in MYC-driven lymphoma. Cancer Discov. 2016;6:59–70.
   PubMed Web of Science ®Google Scholar
• Harrison SJ, Khot A, Brajanovski N, et al. A phase 1, open-label, dose escalation, safety, PK and PD study of a first in class Pol1 inhibitor (CX-5461) in patients with advanced hematologic malignancies (HM). J Clin Oncol. 2015;33:e22212.
   Web of Science ®Google Scholar
• Khot A, Brajanovski N, Cameron D, et al. First-in-human RNA polymerase I transcription inhibitor CX-5461 in patients with advanced hematologic cancers: results of a phase I dose-escalation study. Cancer Discov. 2019;9:1036–1049.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–458.
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul. 1984;22:27–55.
   PubMedGoogle Scholar